# CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

> **NCT02580448** · PHASE1,PHASE2 · COMPLETED · sponsor: **Innocrin Pharmaceutical** · enrollment: 175 (estimated)

## Conditions studied

- Cancer of the Breast
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Male Breast Cancer
- Triple Negative Breast Cancer
- ER+ Breast Cancer

## Interventions

- **DRUG:** Seviteronel

## Key facts

- **NCT ID:** NCT02580448
- **Lead sponsor:** Innocrin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580448, "CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02580448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*